Osmbek Producer is preparing to launch a new weight to lose weight

“Novo Nordisk” enterprise prepares a drug “Ozmbek”, to detect a new weight to lose weight, believing it can lead the field of GLP-1 treatments, while pharmaceutical companies want to improve the results of popular properties such as “Wigofi” and “Monjofo”, according to financial times. The company expects the recent data for “Kajri Sima”, which is expected to be published next month, will appear that the property will reduce by 25% in just one year. This is compared to up to 16% of the “Wigofi” site of “Novo Nordsk”, and up to 22.5% of the rival “Monjo”, produced by the American company “Eli Lily”, in collaboration with changing lifestyle such as improving diet, exercising and sleeping. “The Kajri property is very important to us, it is a producer of the next generation and has the ability to be the best in his class.” The results of the most important experiments will be closely monitored by the pharmaceutical experts. The shares of “Novo Nordsk”, which remains the largest company in Europe in terms of market value, are fighting to keep up with the most important competitor’s shares in the weight loss sector “Eli Lily” producer of the “Monjo” site. Investors’ confidence in the “Novo Nordisk” ability to meet demand for its products was influenced, while the company also had a setback in September last year to the disappointing results of the experimental weight loss pills. Yorgensen said that the company could meet demand, and that the movements of share prices “show the presence of many noise over obesity and perhaps a misunderstanding about the basic work position.” Data associated with weight loss medicine shakes the share prices in the pharmaceutical sector, where excitement on medicine has dominated the evaluation of the operating prospects over the past year. The shares of “Roche” rose in July last year, when it revealed early data on weight loss pills, but in September took off against the background of concerns about the side effects. And if the medicine ‘Kajri Sima’ fails to achieve its advertised abilities, investors may begin to revise the ability of ‘Novo Nordek’ to lead the field of weight loss, according to analyst at Barclays Bank, Emily Field. How does “Kajry Sima” work? The “Kajri Sima” medicine combines semaglutide, which is the active component of the treatment of “ozmbek” and “wigofi” that produces the company that simulates the GLP-1 dormant, with Cagrilintide, a compound based on the hormone of the pancreas “amylene”, in a weekly injection. Although the company is not expected to publish “Novo Nordisk” next month detailed data, the results of “Cagery Sima” will be the most advanced in connection with the drug “Amilin”. This will be broader meaning in this area, as other medicine businesses develop amileen-based treatments, such as the GLP-1, which eats and the body helps control the levels of glucose in the blood. Michael Novod, an “Nordia” analyst, said that the success of “Kajri Sima” could increase the confidence in companies such as the Danish organization “Zeland Pharma”, which works to develop a property that depends only on “Amelin”. Its market value has doubled this year in light of the increasing interest as this category of real estate. A variety of adopted weight loss medicine can offer doctors different options to prescribe patients who need to lose greater weight or suffer from side effects. “There will be a single type that fits everyone,” Novod explained. He added that the data occupies an important level similar to the advanced data of the “Ozmbeak”, “Montgogro” and “Celtic” experiences, which proved the benefits of GLP-1 medicine in the treatment of cases such as heart disease. He considers it an important moment of the company’s ability to innovate and set a new goal for other medicines. ‘